Evofem Biosciences, INC 10-K annual reports
Annual reports — audited financials, the full risk-factor list, and management’s account of the year.
OID
Evofem Biosciences files an amendment to its annual report on Form 10-K to correct an error in the independent auditor's consent regarding the audit opinion and fiscal year-end dates.
OID
Evofem Biosciences reports its annual results, highlighting ongoing financial challenges and the potential impact of the Aditxt merger, while navigating market competition and regulatory landscapes.
OID
Evofem Biosciences reports its 2023 financial results, highlighting a revenue increase despite reduced unit sales, while also navigating a merger agreement with Aditxt.